Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

r moderate in severity and included headaches and minor musculoskeletal and respiratory complaints. All of these events occurred with similar frequency in the three treatment groups. There was one case of peripheral edema in the placebo arm and one case of peripheral edema in one of the treated arms. There were no increases in liver enzymes above 2 times the upper limit of normal. On average, liver enzyme levels tended to decrease from baseline in the treated arms. There were no serious adverse events on PS433540 treatment. Three subjects discontinued therapy for adverse events, all of which were in the placebo group.

The leading, single-therapy antihypertensives across a broad range of classes, according to their labels, have the ability to lower seated office blood pressure up to 12/8mmHg.(1) Data show that a 2mmHg reduction in blood pressure decreases the average death rate from coronary heart disease by an estimated 4 percent and stroke by 6 percent.(2)

"These positive results indicate that PS433540 may be a unique new treatment option for physicians and patients," said Joel Neutel, M.D., Associate Professor of Medicine in the Department of Medicine at the University of California in Irvine, and Medical Director of Clinical Pharmacology at the Orange County Research Center in Tustin, CA, who was the lead investigator of the Phase 2a study. "The magnitude of the blood pressure reductions we saw in this study were very impressive, and we look forward to further evaluating the benefits of this novel compound."

An estimated 73 million Americans suffer from high blood pressure, a major risk factor for cardiovascular events and heart disease.(3) More than half of people diagnosed and treated with high blood pressure never reach suggested treatment goals and those who do often require two or more medications.(4) PS433540 is the first and only compound specifically designed to incorporate two proven mechanisms -- endothelin (ETA) and angiotensin (AT
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 International Isotopes Inc. (OTCQB: ... year ended December 31, 2014.  The Company reports a ... loss, and positive cash flow for the year ended ... in 2014 was approximately $7.5 million compared to approximately ... approximately 10%.  With the exception of the radiological services ...
(Date:4/1/2015)... , April 1, 2015 ... Report on Global Azithromycin Industry and 2015 ... Industry reports added to Pharmaceutical category in ... the report introduces Azithromycin basic information, including ... overview, policy analysis, and news analysis, etc. ...
(Date:4/1/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Glucose Clamp Study. The study will be performed at ... San Antonio and University Health System,s ... Ralph DeFronzo . The glucose clamp is ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3
... YORK, July 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0574348/European-Medical-Displays-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This research ... market in terms of the challenges faced ...
... drug companies face a number of obstacles to commercialize ... (FDA) and GMP compliance, to distribution agreements and the ... must be coordinated.  Those issues have just become easier ... VPCI have entered into a joint association.  The collaboration ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Spanish Drug Companies Have New Support Option for the U.S. Market 2
(Date:4/1/2015)... With so much wet weather over the past few months, ... indoors. When all this time is spent inside, it is ... from Clean Crawls offers excellent advice to homeowners seeking ... One of the ways to improve the air quality in ... states that, “Toluene, Xylene, and Benzene are all Volatile Organic ...
(Date:4/1/2015)... San Mateo, CA (PRWEB) April 01, 2015 ... share $100,200 in athletics grants from California Casualty ... receive free or reduced-cost lunches and subsequently have fewer ... grant is named after California Casualty Chairman Emeritus Thomas ... the field translated to the classroom. Since its ...
(Date:4/1/2015)... Denver, Colorado (PRWEB) April 01, 2015 The ... the time (4:20 p.m.) when a group of California teenagers ... , However it started, 420 has since become a short-hand ... has evolved into something of a national holiday for the ... WeedLife Network, a rapidly-growing group of websites that help bring ...
(Date:4/1/2015)... West Orange, NJ (PRWEB) April 01, 2015 ... seem as important as just finding some relief. Identifying the ... determining a solution. In many cases, the cause of chronic ... even more common than other diagnosable causes of back pain ... MD, PhD , founder and president of Atlantic Spine ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 TCS ... clinical solutions for the care management and population health ... the collaboration portal Acuity Connect, which is fully integrated ... April 15, 2015 at 1:30 p.m. ET, will be ... Development at TCS. It will explore the feature-rich portal ...
Breaking Medicine News(10 mins):Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5Health News:The WeedLife Network Marks the Marijuana Culture’s 420 Celebrations by Offering Steep Advertising Discounts 2Health News:The WeedLife Network Marks the Marijuana Culture’s 420 Celebrations by Offering Steep Advertising Discounts 3Health News:Demystifying Facet Joint Syndrome 2Health News:Demystifying Facet Joint Syndrome 3Health News:Demystifying Facet Joint Syndrome 4Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3
... babies tend to have lower IQs.While the differences are too ... importance at a population level.// , ... age seven to study the relationship between birth weight and ... directly related to birth weight, while factors such as the ...
... for prostate cancers has been found out by researchers.// This ... exam for prostate cancer, the doctor takes six tissue samples ... researchers said that it is better to take more samples. ... sector biopsy. They took 12 samples - six ...
... itchy flaky scalp to give it a more common name. ... using a medicated shampoo, but be aware that you may// need ... lose their effectiveness. Ideally, wash your hair with the shampoo every ... with your scalp by leaving it for a few minutes. ...
... Pediatrics issued new recommendations telling pediatricians to screen all ... of a serious illness. Children who snore loudly may// ... the disorder can lead to growth, heart and pulmonary ... of patients older than age 1, the pediatricians' group ...
... researchers, increased levels of the hormone leptin may explain why ... clotting// that causes heart attack and strokes.It is well known ... problems.Now researchers at the University of Michigan are one step ... the role of the hormone leptin in making the blood ...
... progression of cancer in 7 out of 10 patients ... given to patients with a variety of cancers that ... the Ohio-based Cleveland Clinic. ,Phenoxodiol belongs to ... transduction inhibitors, all designed to switch off certain cancer ...
Cached Medicine News:
... a Windows NT client server system that ... versatility, power and high-speed volume required to ... by industry experts, LabNet is structured to ... easy and effective as possible. Our system ...
comprehensive LIS solutions for Physician Office Laboratories are designed to fill the needs of any POL, large or small. Includes 2 additional standard instrument interfaces for a total of 3 standard...
... Tiburon™ surgical drapes from Cardinal Health will ... and draping in your facility. , ,Shrinking ... be carefully controlled at every turn without ... patient outcomes. Each decision must be evaluated ...
... NEAR-SkinT™ Incise Drapes have aggressive ... permeability for extended adhesion. It's made ... for unsurpassed conformability with allow-glare matte ... identification. , ,Available sterile in ...
Medicine Products: